Quality of Life Assessment in Multiple Sclerosis Management

Quality of life (QoL) assessment has moved from a secondary consideration to a central pillar in the management of multiple sclerosis (MS). As a chronic, heterogeneous neurological condition, MS imposes physical disability, cognitive impairment and emotional burden that evolve over time. Conventional metrics such as relapse rate and lesion load on magnetic resonance imaging capture disease activity but fail to reflect the patient’s lived experience. Modern care pathways therefore integrate patient-reported outcomes (PROs) and disease-specific scales to evaluate physical function, mental health, social participation and fatigue. The choice of instrument influences the sensitivity and comparability of results: generic measures enable economic evaluation and cross-disease comparisons, while MS-tailored tools capture nuances of spasticity, cognitive slowing and psychosocial impact. Robust QoL assessment supports shared decision-making, guides treatment selection, underpins regulatory approval of disease-modifying therapies (DMTs) and informs rehabilitation and self-management programmes. Globally, there is a growing consensus on the need for harmonised, validated instruments that are reliable, responsive to change and feasible in routine practice. Embedding QoL assessment into clinical trials and real-world data collection ensures that therapeutic advances translate into meaningful gains for people living with MS.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Quality of Life Assessment in Multiple Sclerosis Management publication trend

The graph below shows the total number of articles in quality of life assessment in multiple sclerosis management across all publications each year (not limited to Nature Index journals).

Technical terms

Quality of life (QoL): A multidimensional construct encompassing physical health, psychological state, social relationships and functional abilities as experienced by the patient.

Patient-reported outcome (PRO): Any health-related report coming directly from the patient without external interpretation, used to assess symptoms, function or quality of life.

Disease-modifying therapy (DMT): A treatment designed to alter the underlying course of MS by reducing relapse frequency, delaying progression or modulating immunological activity.

Expanded Disability Status Scale (EDSS): A clinician-administered scale ranging from 0 (normal neurological examination) to 10 (death due to MS) used to quantify disability and monitor disease progression.

Patient Determined Disease Steps (PDDS): A patient-completed scale that correlates with the EDSS to measure self-perceived disability in daily activities.

Multiple Sclerosis Impact Scale (MSIS-29): A disease-specific questionnaire assessing the physical and psychological impact of MS on quality of life.

Digital care pathway (DCP): An online platform providing tailored education, monitoring and communication tools to support patients and clinicians in MS management.

References

1. Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis. Journal of Neurology (2024).
2. Effects of a Digital Care Pathway for Multiple Sclerosis: Observational Study. JMIR Human Factors (2024).
3. Effect of patient-centered and family-centered self-care education program on the quality of life of patients with multiple sclerosis: a quasi-experimental study. BMC Nursing (2023).